Amicus Therapeutics (NASDAQ:FOLD) Stock

AMICUS THERAPEUTICS INC

Amicus Therapeutics

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Inc

Fold Holdings, Inc. - Class A Common Stock

Fold Holdings Inc

PROPEL was a 52-week, double-blind randomized global study designed to assess the efficacy, safety, and tolerability of cipaglucosidase alfa-atga + miglustat compared to non-U.S. approved alglucosidase alfa + placebo (the comparator). The study enrolled 123 adult LOPD patients who still had the ability to walk and to breathe without mechanical ventilation.
Patients enrolled in PROPEL were randomized 2:1 so that for every two patients randomized to be treated with cipaglucosidase alfa-atga + miglustat, one was randomized to be treated with the comparator. Of the patients enrolled in PROPEL, 77% were being treated with alglucosidase alfa (n=95) for at least 2 years at study entry and 23% had never been treated with any ERT (n=28). 117 of the 123 patients (&gt;95%) completed the PROPEL study.
Efficacy endpoints of the study included primary endpoint of change from baseline to week 52 in 6-minute walk distance (6MWD) for comparison of superiority and key secondary endpoint of change from baseline to week 52 in forced vital capacity (FVC). PROPEL did not achieve statistical significance for the primary endpoint of superiority in change from baseline to week 52 in 6MWD in the overall population. After 52 weeks, ERT-experienced patients treated with cipaglucosidase alfa-atga + miglustat (n=61) walked an estimated 17 meters (95% CI, 0.2, 33) farther than the comparator group (n=29). After 52 weeks, ERT-experienced patients treated with cipaglucosidase alfa-atga + miglustat (n=55) showed an estimated treatment difference of 3.5% (95% CI, 1.0, 6.0) in FVC compared with the comparator group (n=29).
More details about this post-hoc analysis
<ul>
<li>This post-hoc analysis assessed the magnitude of within-group treatment effects across measures of motor function, muscle strength, pulmonary function, patient-reported outcomes/QoL measures, and biomarkers. Standardized effect size analysis describes the absolute effect size relative to the variability of the data. It transforms the effect size into a scale with no units of measurement (Cohen's&nbsp;d). The authors calculated standardized within-group effect sizes (Cohen's d for within-group comparisons) and corresponding 95% CIs for the change from baseline to week 52 for the primary, secondary, and pharmacodynamic endpoints of the PROPEL study. Standardized within-group effect sizes and corresponding 95% CIs were calculated by dividing the mean change from baseline values and CIs at week 52 by the standard deviation (SD) of the difference scores. Consistent with medical literature, effect sizes were defined as stable (−0.2 &lt; d &lt; 0.2), small (0.2 ≤ d &lt; 0.5), medium (0.5 ≤ d &lt; 0.8), or large (d ≥ 0.8) improvement, or as small (−0.5 &lt; d ≤ −0.2), medium (−0.8 &lt; d ≤ −0.5), or large (d ≤ −0.8) worsening, and were considered statistically significant if the standardized 95% CIs did not cross zero.</li>
</ul>

Biotech

News

Health Care

General

FOLD

Amicus Therapeutics Announced The Publication Of A Post-hoc Analysis Of Data From The Ert-experienced Cohort Of The PROPEL Study Of Cipaglucosidase Alfa-Atga + Miglustat (Cipa+Mig) In Adults With Late-onset Pompe Disease In Muscle And Nerve

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Buy and raises the price target from $21 to $22.

Price Target

Analyst Ratings

UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22

Goldman Sachs analyst Salveen Richter maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Neutral and lowers the price target from $12 to $9.

Goldman Sachs Maintains Neutral on Amicus Therapeutics, Lowers Price Target to $9

WIIM

Amicus Therapeutics shares are trading lower after the company reported mixed Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 68.2% to $4.81 during Thursday's pre-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 36.2% to $0.02. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 28.98% to $0.89. The market value of their outstanding shares is at $5.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock moved upwards by 11.56% to $3.28. The market value of their outstanding shares is at $123.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares moved upwards by 10.63% to $1.55. The company's market cap stands at $48.5 million. </li>
<li>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) stock increased by 10.42% to $54.23. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) stock fell 31.3% to $6.61 during Thursday's pre-market session. The market value of their outstanding shares is at $454.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) stock decreased by 16.71% to $10.77. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q1 earnings report came out today. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 14.65% to $2.68. The market value of their outstanding shares is at $12.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 12.08% to $0.4. The market value of their outstanding shares is at $1.8 million. </li>
<li>Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) stock decreased by 11.72% to $6.78. The market value of their outstanding shares is at $2.0 billion. The company's, Q1 earnings came out today. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock fell 10.9% to $9.0. The company's market cap stands at $119.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACRV

ADIL

ARVN

BCDA

CNMD

GLSI

LGMK

NAOV

SERA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Guidance

Amicus Therapeutics Sees FY25 Revenue Growth Of 17% - 24%

Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.05) by 160 percent. This is a 250 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $125.20 million which missed the analyst consensus estimate of $135.86 million by 7.85 percent. This is a 13.40 percent increase over sales of $110.40 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Amicus Therapeutics Q1 Adj. EPS $0.03 Beats $(0.05) Estimate, Sales $125.20M Miss $135.86M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

<ul>
<li>Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies</li>
<li>Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval</li>
<li>Dimerix to receive US$30 million (~AU$48 million) upfront payment, up to US$560 million (~AU$892 million) for success-based milestone payments, in addition to tiered royalties on DMX-200 net U.S. sales</li>
</ul>

Reported Earlier, Dimerix And Amicus Therapeutics Sign Exclusive U.S. License Agreement For DMX-200 In FSGS Treatment

Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Amicus Therapeutics will report an earnings per share (EPS) of $0.08.
The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 5.13% drop in the share price the following trading session.
Here's a look at Amicus Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0</td>
<td>-0.05</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.09</td>
<td>0.1</td>
<td>0.06</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746028887_0.png" alt="eps graph" />
<h3>Performance of Amicus Therapeutics Shares</h3>
Shares of Amicus Therapeutics were trading at $7.52 as of April 29. Over the last 52-week period, shares are down 27.89%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Views on Amicus Therapeutics</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Amicus Therapeutics.
A total of 1 analyst ratings have been received for Amicus Therapeutics, with the consensus rating being Outperform. The average one-year price target stands at $17.0, suggesting a potential 126.06% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Recursion Pharmaceuticals, Apellis Pharmaceuticals and Twist Bioscience, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Recursion Pharmaceuticals, with an average 1-year price target of $9.0, suggesting a potential 19.68% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Apellis Pharmaceuticals, with an average 1-year price target of $38.89, suggesting a potential 417.15% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Twist Bioscience, with an average 1-year price target of $50.25, suggesting a potential 568.22% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
Within the peer analysis summary, vital metrics for Recursion Pharmaceuticals, Apellis Pharmaceuticals and Twist Bioscience are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amicus Therapeutics</td>
<td>Outperform</td>
<td>30.09%</td>
<td>$134.87M</td>
<td>7.91%</td>
</tr>
<tr>
<td>Recursion Pharmaceuticals</td>
<td>Buy</td>
<td>-57.54%</td>
<td>$-8.28M</td>
<td>-22.95%</td>
</tr>
<tr>
<td>Apellis Pharmaceuticals</td>
<td>Neutral</td>
<td>45.19%</td>
<td>$171.67M</td>
<td>-15.61%</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>Outperform</td>
<td>24.08%</td>
<td>$42.84M</td>
<td>-6.80%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Amicus Therapeutics ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>Unveiling the Story Behind Amicus Therapeutics</h3>
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
<h3>Amicus Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Amicus Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 30.09%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amicus Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.85% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amicus Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.91%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Amicus Therapeutics's ROA excels beyond industry benchmarks, reaching 1.88%. This signifies efficient management of assets and strong financial health.
Debt Management: Amicus Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.29, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/FOLD/earnings">To track all earnings releases for Amicus Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Amicus Therapeutics Earnings Preview

Wells Fargo analyst Tiago Fauth maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and lowers the price target from $18 to $17.

Wells Fargo Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $17

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Amicus Therapeuticsto Hold

2025 Financial Guidance
To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Total Revenue Growth1</td>
<td>17% to 24%</td>
</tr>
<tr>
<td>Galafold Revenue Growth1</td>
<td>10% to 15%</td>
</tr>
<tr>
<td>Pombiliti + Opfolda Growth1</td>
<td>65% to 85%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>Mid 80%</td>
</tr>
<tr>
<td>Non-GAAP Operating Expenses4</td>
<td>$350M to $370M</td>
</tr>
<tr>
<td>GAAP Net Income</td>
<td>Positive during H2 2025</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half

Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.01 by 800 percent. This is a 800 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $149.706 million which beat the analyst consensus estimate of $148.012 million by 1.14 percent. This is a 30.09 percent increase over sales of $115.080 million the same period last year.

Amicus Therapeutics Q4 2024 Adj. EPS $0.09 Beats $0.01 Estimate, Sales $149.706M Beat $148.012M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

EXAS

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

Cantor Fitzgerald analyst Kristen Kluska reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and maintains $21 price target.

Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $21 Price Target

In the preceding three months, 6 analysts have released ratings for Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Amicus Therapeutics, revealing an average target of $16.83, a high estimate of $21.00, and a low estimate of $12.00. Observing a 3.06% increase, the current average has risen from the previous average price target of $16.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736769610_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Amicus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Karl Chalabala</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amicus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Amicus Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Amicus Therapeutics</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Amicus Therapeutics: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Amicus Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 36.73%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Amicus Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Amicus Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Amicus Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -0.88%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.49, Amicus Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Hold.

Needham Reiterates Hold on Amicus Therapeutics

<ul>
<li>2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1</li>
<li>Strong and Growing Demand for Galafold&#xAE; and Pombiliti&#xAE; + Opfolda&#xAE;</li>
<li>Total Revenue Growth of 17-24% at CER Expected in 2025</li>
<li>&gt;3,000 People Treated with an Amicus Therapy Today2</li>
</ul>

Reported Earlier, Amicus Reported $528M In 2024 Revenue (+32% YoY), Projects 17-24% Growth In 2025, And Highlights First Full Year Of Pombiliti + Opfolda Sales

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384005/amicus-therapeutics-settles-patent-lawsuit-teva-pharmaceuticals-over-generic-version-of-its-rare-" rel="noreferrer noopener">Galafold patent litigation</a> with Teva Pharmaceutical Industries Ltd.
The analyst notes that Amicus is well-positioned, but expectations have increased with the company&#8217;s progress, which are now largely priced into shares.
The analyst downgraded the stock to Equal-weight from Overweight and lowered the price <a target="_blank" href="https://www.benzinga.com/quote/FOLD/analyst-ratings" rel="noreferrer noopener">target from $17 to $12</a>.
Investors have shifted focus to what will provide the company&#8217;s next leg of growth. The analyst would look to see potential updates to the company&#8217;s pipeline in 2025 and beyond, as those programs have the greatest potential to unlock further value for Amicus stock.
Morgan Stanley has also lowered the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $74 to $35 on launch timing and pricing for brenetafusp given disappointing data earlier this year in cutaneous melanoma <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40864698/immunocore-presents-phase-1-data-of-brenetafusp-an-immtac-bispecific-targeting-prame-in-patients-w" rel="noreferrer noopener">and ovarian cancer</a>.
The analyst continues to give full credit for Kimmtrak (tebentafusp), which was approved for unresectable or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42282399/immunocore-announces-reimbursement-agreement-in-england-for-kimmtrak-for-the-treatment-of-hla-a-02" rel="noreferrer noopener">metastatic uveal melanoma</a>.
Morgan Stanley sees limited upside potential from additional brenetafusp updates as the company continues to detect signals in metastatic NSCLC and combination in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41769749/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update" rel="noreferrer noopener">earlier-line NSCLC</a>.
The analyst downgraded the stock <a target="_blank" href="https://www.benzinga.com/quote/IMCR/analyst-ratings" rel="noreferrer noopener">from Overweight to Equal-Weight rating.</a>
Morgan Stanley downgraded Immuneering Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares to Underweight from Equal-weight and set a base case range of $1 to $5 versus its <a target="_blank" href="https://www.benzinga.com/quote/IMRX/analyst-ratings" rel="noreferrer noopener">previous target of $4</a>. While supporting Immuneering&#8217;s strategy of targeting the MAPK pathway with deep cyclic inhibition, the analyst notes other stronger investment opportunities in the coverage on a relative basis.
Early clinical results have been promising, but analysts emphasize the need for more robust data with a larger patient pool to confirm that these outcomes aren&#8217;t coincidental or limited to specific cases. Additionally, the analyst expressed greater caution regarding the potential of IMM-1-104 in indications <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40852429/why-is-nanocap-immuneering-stock-trading-higher-on-friday" rel="noreferrer noopener">outside of pancreatic cancer</a>.
Price Action: IMRX stock is down 18% at $1.615, IMCR stock is down 5.89% at $28.53, and FOLD stock is down 6.70% at $9.47 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468572/netflix-adjusts-parental-leave-policy-amid-cultural-and-financial-shifts" target="_blank" rel="noreferrer noopener">Netflix Adjusts Parental Leave Policy, But There Is A Catch</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Downgrades

Trading Ideas

IMCR

IMRX

TEVA

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Press Releases

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

Legal

AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Investors to Contact the Firm

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Comments

Amicus Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL